Abcam is the world’s leading monoclonal antibody provider. The Custom Products & Licensing group of Abcam is focusing on developing, selling, and licensing antibodies to commercial partners, most of which are IVD developers and manufacturers for diagnostics or companion diagnostics applications. These companies are using Abcam’s antibodies as the primary antibody for detection of a disease state or condition or suitability to responding to a specific drug (companion Dx).
While in many cases, customers can be using a pre-existing antibody from our large library of recombinant monoclonal antibodies, in other cases, we use one of our advanced antibody development technologies: RabMAb®, AxioMx, or next gen sequencing to develop a custom antibody. In select cases further assay development services are rendered such as IHC validation, simple step ELISA or multiplex assay development via FirePlex® technology.